$599

Teplizumab Approved as Tzield; Sernova Implants First Two Patients in Second Cohort of Ph1/2 T1DM Trial

Two cardiometabolic-related news items have been observed: Provention Bio announced the FDA approval of teplizumab to delay the onset of T1DM; and Sernova announced the first two patients in the second cohort of its Ph1/2 trial in T1DM have been implanted (view CT.gov record). Below, FENIX provides highlights and insights from the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.